Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anthrax Vaccines
Research data from Oregon State University, Department of Pharmaceutical Sciences update understanding of anthrax vaccines
April 30th, 2008
Researchers detail in 'Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens,' new data in anthrax. According to recent research from the United States, "A new generation anthrax vaccine is expected to target not only the anthrax protective antigen (PA) protein, but also other virulent factors of Bacillus anthracis. It is also expected to be amenable for rapid mass immunization of a large number of people." "This study aimed to address these needs by designing a prototypic triantigen nasal anthrax vaccine candidate that contained a truncated PA (rPA63), the anthrax lethal factor (LF), and...
Source: Vaccine Weekly (2008-04-30)
|
